An announcement from Optimi Health ( (TSE:OPTI) ) is now available.
Optimi Health Corp. has announced significant advancements in its operations, including the expansion of MDMA exports to Australia and securing a BICON import permit for psilocybin, allowing its use for treatment-resistant depression. The company has also partnered with ATMA CENA Healthcare Solutions to supply psilocybin for clinical trials targeting major depressive disorder, marking progress towards broader regulatory approvals in Canada. Additionally, Optimi has completed a major harvest of Psilocybe cubensis, which will support upcoming clinical trials and international distribution.
More about Optimi Health
Optimi Health Corp. is a GMP-compliant, Health Canada-licensed manufacturer specializing in botanical psilocybin and MDMA. The company focuses on producing pharmaceutical-grade psychedelic substances for therapeutic use, with a market emphasis on expanding access to these treatments internationally.
YTD Price Performance: -21.43%
Average Trading Volume: 45,572
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$15.91M
For a thorough assessment of OPTI stock, go to TipRanks’ Stock Analysis page.